iCAD CEO and leadership

Mr. Michael Klein serves as the Chairman and CEO for iCAD Medical (Nasdaq: ICAD), a clinical artificial intelligence company focused on the detection of breast cancer and other proliferative diseases. iCAD's, therapy subsidiary, Xoft Inc. uses novel electronic brachytherapy for the treatment of breast and gynecological cancers as well as brain, rectal and prostate cancers. Between December 2014 and October 2018, when he assumed the above position, Mr. Klein served as Chief Executive Officer at Inflection Point Consulting, an executive coaching and consulting firm with a focus on medical technology, biopharma and healthcare services. During this same time period, Mr. Klein served as a Adjunct Professor at the Leavey School of Business at Santa Clara University. Prior to that, from December 2011 to November 2014. Klein was the Chief Executive Officer at SonaCare Medical, LLC (f/k/a US HIFU, LLC), a global leader in minimally invasive high intensity focused ultrasound technologies used for the treatment of prostate and other urological cancers. From April 2011 to December 2011, Mr. Klein was the President of the Civco Radiation Oncology Division within Roper Industries, a diversified industrial company that produces engineered products for global niche markets. He was President and Chief Executive Officer of Xoft, Inc., a medical device company, a position he held from December 2004 until the sale of Xoft to iCAD Medical in December 2010. Prior to joining Xoft, from 2000 to 2004, Mr. Klein served as Chairman, President and Chief Executive Officer of R2 Technology, Inc., a breast and lung cancer computer aided detection company. The first company to bring a medical artificial intelligence technology before the FDA and receive PMA Regulatory Approval. Previously, Mr. Klein served in VP, Sales and Marketing roles at Varian Medical Systems (VAR) and Becton Dickinson (BDX). Mr. Klein received a Bachelor of Arts degree from the University at Albany, SUNY. Mr. Klein also received his M.B.A. from the New York Institute of Technology and completed his post-graduate Executive Education Studies at Harvard University and Babson College. Mr. Klein lives in Mountain View, California with his wife and 3 children, in close proximity. Mr. Klein splits time between iCAD headquarters in Nashau, NH and Xoft’s headquarters in San Jose, CA.

Jonathan Go brings more than twenty years of software development experience in the medical industry to his position as Senior Vice President of Research and Development at iCAD. Prior to joining iCAD, Go served as Vice President of Engineering at Merge eMed, a provider of RIS/PACS solutions for imaging centers, specialty practices and hospitals. At Merge eMed, Go was responsible for software development, product management, testing, system integration and technical support for all of eMed's products. Before joining Merge eMed, Go was Director of Engineering at Cedara Software in Toronto. Cedara Software is focused on the development of custom engineered software applications and development tools for the medical imaging OEMs. At Cedara, Go built the workstation program, developing multiple specialty workstations that have been adopted by a large number of OEM partners. Go earned a Bachelor of Science in Electrical Engineering from the University of Michigan and a Masters of Science in Electrical Engineering and Biomedical Engineering from the University of Michigan.

Finance executive/consultant with advanced science degree, top 5 MBA, strategy consulting partnership, and 15 years complex operational financial management experience in multiple industries. Primary function in finance and accounting (including technical accounting, remediation, and audit management), operational planning and reporting, strategy development, data collection/analysis, and decision support. Experience leading business development (including deal structuring and valuation analysis), program management, legal, clinical operations, IT, HR, real estate, commercial launch/support, and scientific support. Experience includes - R&D stage to commercial; products to services to blended offerings; $1.6BB public to small, private early-stage companies; local to global footprints; private sector to non-profit government contracts. Industries have all included high operational complexity and critical regulatory compliance. Have led large groups, cross-functionally participated, and individually contributed as needs dictated. Experience includes domestic and global post-merger implementation experience and various financial systems implementations.

Focused on both life sciences and human services/education businesses

Specialties: Finance, accounting, fundraising, general management, G&A, planning and strategy, financial modeling, controls and business process design, business development and valuation, systems implementation and IT management.

Mr. Michael Klein serves as the Chairman and CEO for iCAD Medical (Nasdaq: ICAD), a clinical artificial intelligence company focused on the detection of breast cancer and other proliferative diseases. iCAD's, therapy subsidiary, Xoft Inc. uses novel electronic brachytherapy for the treatment of breast and gynecological cancers as well as brain, rectal and prostate cancers. Between December 2014 and October 2018, when he assumed the above position, Mr. Klein served as Chief Executive Officer at Inflection Point Consulting, an executive coaching and consulting firm with a focus on medical technology, biopharma and healthcare services. During this same time period, Mr. Klein served as a Adjunct Professor at the Leavey School of Business at Santa Clara University. Prior to that, from December 2011 to November 2014. Klein was the Chief Executive Officer at SonaCare Medical, LLC (f/k/a US HIFU, LLC), a global leader in minimally invasive high intensity focused ultrasound technologies used for the treatment of prostate and other urological cancers. From April 2011 to December 2011, Mr. Klein was the President of the Civco Radiation Oncology Division within Roper Industries, a diversified industrial company that produces engineered products for global niche markets. He was President and Chief Executive Officer of Xoft, Inc., a medical device company, a position he held from December 2004 until the sale of Xoft to iCAD Medical in December 2010. Prior to joining Xoft, from 2000 to 2004, Mr. Klein served as Chairman, President and Chief Executive Officer of R2 Technology, Inc., a breast and lung cancer computer aided detection company. The first company to bring a medical artificial intelligence technology before the FDA and receive PMA Regulatory Approval. Previously, Mr. Klein served in VP, Sales and Marketing roles at Varian Medical Systems (VAR) and Becton Dickinson (BDX). Mr. Klein received a Bachelor of Arts degree from the University at Albany, SUNY. Mr. Klein also received his M.B.A. from the New York Institute of Technology and completed his post-graduate Executive Education Studies at Harvard University and Babson College. Mr. Klein lives in Mountain View, California with his wife and 3 children, in close proximity. Mr. Klein splits time between iCAD headquarters in Nashau, NH and Xoft’s headquarters in San Jose, CA.